These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34001723)

  • 21. Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension.
    Verweij P; Danaietash P; Flamion B; Ménard J; Bellet M
    Hypertension; 2020 Apr; 75(4):956-965. PubMed ID: 32063059
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel dual action AT1 and ETA receptor antagonists reduce blood pressure in experimental hypertension.
    Kowala MC; Murugesan N; Tellew J; Carlson K; Monshizadegan H; Ryan C; Gu Z; Kane B; Fadnis L; Baska RA; Beyer S; Arthur S; Dickinson K; Zhang D; Perrone M; Ferrer P; Giancarli M; Baumann J; Bird E; Panchal B; Yang Y; Trippodo N; Barrish J; Macor JE
    J Pharmacol Exp Ther; 2004 Apr; 309(1):275-84. PubMed ID: 14718594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impaired endothelin calcium signaling coupled to endothelin type B receptors in penile arteries from insulin-resistant obese Zucker rats.
    Contreras C; Sánchez A; Martínez P; Climent B; Benedito S; García-Sacristán A; Hernández M; Prieto D
    J Sex Med; 2013 Sep; 10(9):2141-53. PubMed ID: 23875673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vascular Effects of Endothelin Receptor Antagonists Depends on Their Selectivity for ETA Versus ETB Receptors and on the Functionality of Endothelial ETB Receptors.
    Iglarz M; Steiner P; Wanner D; Rey M; Hess P; Clozel M
    J Cardiovasc Pharmacol; 2015 Oct; 66(4):332-7. PubMed ID: 25992919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual endothelin receptor antagonists contrast the effects induced by endothelin-1 on cultured human microvascular endothelial cells.
    Soldano S; Paolino S; Pizzorni C; Trombetta AC; Montagna P; Brizzolara R; Corallo C; Giordano N; Sulli A; Cutolo M
    Clin Exp Rheumatol; 2017; 35(3):484-493. PubMed ID: 28134077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. After 30 years, the first endothelin-receptor antagonist (Aprocitentan) is approved for the treatment of arterial hypertension.
    Tamargo J
    Eur Heart J Cardiovasc Pharmacother; 2024 Aug; 10(5):371-373. PubMed ID: 38754980
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentan.
    Sidharta PN; Treiber A; Dingemanse J
    Clin Pharmacokinet; 2015 May; 54(5):457-71. PubMed ID: 25860376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Celecoxib, but not indomethacin, ameliorates the hypertensive and perivascular fibrotic actions of cyclosporine in rats: role of endothelin signaling.
    El-Mas MM; Helmy MW; Ali RM; El-Gowelli HM
    Toxicol Appl Pharmacol; 2015 Apr; 284(1):1-7. PubMed ID: 25656942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endothelin receptor antagonists and their developing role in cardiovascular therapeutics.
    Dupuis J
    Can J Cardiol; 2000 Jul; 16(7):903-10. PubMed ID: 10934309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renal damage is not improved by blockade of endothelin receptors in primary renin-dependent hypertension.
    Rothermund L; Kossmehl P; Neumayer HH; Paul M; Kreutz R
    J Hypertens; 2003 Dec; 21(12):2389-97. PubMed ID: 14654760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Macitentan: first global approval.
    Patel T; McKeage K
    Drugs; 2014 Jan; 74(1):127-33. PubMed ID: 24297706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In-vivo interaction of nitric oxide and endothelin.
    Hocher B; Schwarz A; Slowinski T; Bachmann S; Pfeilschifter J; Neumayer HH; Bauer C
    J Hypertens; 2004 Jan; 22(1):111-9. PubMed ID: 15106802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The endothelin-aldosterone axis and cardiovascular diseases.
    Rossi GP; Cavallin M; Nussdorfer GG; Pessina AC
    J Cardiovasc Pharmacol; 2001 Nov; 38 Suppl 2():S49-52. PubMed ID: 11811378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alterations in vascular matrix metalloproteinase due to ageing and chronic hypertension: effects of endothelin receptor blockade.
    Spiers JP; Kelso EJ; Siah WF; Edge G; Song G; McDermott BJ; Hennessy M
    J Hypertens; 2005 Sep; 23(9):1717-24. PubMed ID: 16093917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of the endothelin system in secondary pulmonary hypertension related to air embolism: lessons learned from testing four classes of endothelin blockers in a rat model.
    Battistini B; Verreault M; Ayach B; Blouin A; Cernacek P; Jeng AY; Wessale J; Opgenorth T; Tsang J
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S386-9. PubMed ID: 15838327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological characterization of YM598, a selective endothelin-A receptor antagonist.
    Sudoh K; Yuyama H; Noguchi Y; Fujimori A; Ukai M; Ohtake A; Sato S; Sasamata M; Miyata K
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S390-3. PubMed ID: 15838329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Multiple-Dose Administration of Aprocitentan on the Pharmacokinetics of Rosuvastatin.
    Sidharta PN; Dingemanse J
    Clin Pharmacol Drug Dev; 2020 Nov; 9(8):995-1002. PubMed ID: 32592633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute effects of endothelin receptor antagonists on hepatic hemodynamics of cirrhotic and noncirrhotic rats.
    Cavasin MA; Semus H; Pitts K; Peng Y; Sandoval J; Chapo J; Plato CF
    Can J Physiol Pharmacol; 2010 Jun; 88(6):636-43. PubMed ID: 20628429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Roles of renin-angiotensin and endothelin systems in development of diastolic heart failure in hypertensive hearts.
    Yamamoto K; Masuyama T; Sakata Y; Mano T; Nishikawa N; Kondo H; Akehi N; Kuzuya T; Miwa T; Hori M
    Cardiovasc Res; 2000 Aug; 47(2):274-83. PubMed ID: 10946064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endothelin 1 type a receptor antagonism prevents vascular dysfunction and hypertension induced by 11beta-hydroxysteroid dehydrogenase inhibition: role of nitric oxide.
    Ruschitzka F; Quaschning T; Noll G; deGottardi A; Rossier MF; Enseleit F; Hürlimann D; Lüscher TF; Shaw SG
    Circulation; 2001 Jun; 103(25):3129-35. PubMed ID: 11425780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.